Procept Biorobotics Corp

PRCT remains in a confirmed Stage 4 decline, trading below all declining EMAs with the active Lower Highs & Lower Lows pattern underscoring continuation risk. Medium-term bias is bearish; execution should be deferred until a rally into the declining 9EMA/20EMA zone for rejection at resistance provides a structurally appropriate sell opportunity.

• ↑Q1 2026 revenue grew 20% YoY to $83.1M on strong U.S. procedure volumes
• ↑Full-year guidance of $390–410M targets 27–33% growth on 60k–64k procedures
• ↓Q1 net loss widened to $31.6M from $24.7M YoY, weakening profitability outlook